التفاصيل البيبلوغرافية
| العنوان: |
In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry. |
| المؤلفون: |
Esposito, Silvano, Pagliano, Pasquale, De Simone, Giuseppe, Guarino, Amedeo, Pan, Angelo, Brambilla, Paola, Mastroianni, Claudio, Lichtner, Miriam, Brugnaro, Pierluigi, Carretta, Anna, Santantonio, Teresa, Brindicci, Gaetano, Carrega, Giuliana, Montagnani, Francesca, Lapadula, Giuseppe, Spolti, Anna, Luzzati, Roberto, Schiaroli, Elisabetta, Scaglione, Vittoria, Pallotto, Carlo |
| المصدر: |
Infection; Aug2024, Vol. 52 Issue 4, p1297-1306, 10p |
| مصطلحات موضوعية: |
INTRAVENOUS therapy, DRUG efficacy, PEPTIDE antibiotics, DRUG tolerance |
| مستخلص: |
Purpose: Although dalbavancin is currently approved for the treatment of ABSSIs, several studies suggest its efficacy and tolerance as long-term therapy for other off-label indications requiring prolonged intravenous antibiotic administration. Methods: We conducted a prospective nationwide study of dalbavancin use in real-life settings for both approved and off-label indications analysing for each case the clinical and microbiological characteristics of infection the efficacy and safety of treatments. Results: During the study period (from December 2018 to July 2021), the ID specialists from 14 different centres enrolled 223 patients treated with dalbavancin [141 males (63%) and 82 females (37%); male/female ratio 1.72; mean age 59 (SD 17.2) years, (range 15–96). Most patients in the study population (136/223; 61.0%) came from community rather than health care facilities and most of them were visited in Infectious Diseases wards (93/223; 41.7%) and clinics (55/223; 24.7%) even though some patients were cured in other settings, such as surgery wards (18/223; 8.1%), orthopaedic wards (11/223; 4.9%), Emergency Rooms (7/223; 3.1%) and non-surgical other than ID wards (6/223; 2.7%). The most common ID diagnoses were osteomyelitis (44 cases/223; 19.7%; of which 29 acute and 15 chronic osteomyelitis), cellulitis (28/223; 12.5%), cutaneous abscess (23/223; 10.3%), orthopaedic prosthesis-associated infection (22/223; 9.9%), surgical site infection (20/223; 9.0%) and septic arthritis (15/223; 6.7%). Conclusion: In conclusion, by virtue of its PK/PD properties, dalbavancin represents a valuable option to daily in-hospital intravenous or outpatient antimicrobial regimens also for off-label indications requiring a long-term treatment of Gram-positive infections. [ABSTRACT FROM AUTHOR] |
|
Copyright of Infection is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Find this article in full text from Springer Verlag. 
Full Text Finder